Necessities · Markets · Australia

Why Australia.

6 min read AU

The window

Australia. In-flight regulations by year.

2024 1 2025 1 2026 1 2027 8 2028 0 2029 0 2030 0 Peak crystallisation 2027. 8 regulations

Each bar counts effective dates in Australia between 2024 and 2030.

Source: hmm Ventures regulatory dataset.

The Necessity Doctrine, Chapter 5

Australia is where regulatory architecture, R&D incentives, and superannuation capital intersect. The R&D Tax Incentive reduces the effective cost of eligible technical work for early-stage R&D businesses. The A$4.3 trillion superannuation pool is being slowly redirected toward unlisted growth equity by both regulatory pressure and political reform. The four sectors with the deepest regulatory architecture (mining, financial services, healthcare, and energy) are the four sectors where the country’s industrial capability is greatest.

The Necessities here is the simplest of the four markets. Australia is attractive because regulation, incentives, and capital formation reinforce each other: subsidised R&D, a domestic capital pool large enough to absorb a series-stage market, and mature regulatory regimes in every Necessity-aligned sector. The risk is execution at the LP-allocator level. Superannuation funds are slow to commit, and political volatility can change the R&D incentive parameters between vintages.

Australia, current state

  • R&D Tax Incentive: 43.5% refundable offset for companies with aggregated turnover under A$20M; non-refundable offset for larger companies, up to an A$150M expenditure threshold.1
  • Superannuation pool: approximately A$4.3 trillion; allocation to unlisted growth assets in the high single digits to low double digits across major industry funds.2
  • Concessional tax cap: 30% concessional rate applies to superannuation balances above A$3M from 1 July 2026, following Better Targeted Superannuation Concessions passage in 2025.3
  • Regulatory architecture: APRA, ASIC, AEMO, TGA, FIRB, ASX cover the four Necessity-aligned regulated sectors. Each has discrete compliance and approval pathways.

The R&D Tax Incentive as a cost-of-capital line

The Australian R&D Tax Incentive (RDTI) returns 43.5 cents per dollar of eligible R&D expenditure for sub-A$20M turnover companies, claimed back through the tax system 12-18 months after deployment.1 The eligible-spend definition narrows what counts: technical R&D activities, not the full burn.

The mechanic matters at the deal level. If most of a seed-stage company’s A$3M annual burn qualifies as eligible R&D, the post-offset cash cost can be materially lower than the headline number, subject to eligibility and the 12-18 month timing lag. A comparable California company can access federal Section 41 and Section 174 R&D credits and SBIR/STTR programmes, but not a directly comparable refundable offset at the same scale for early-stage losses. That creates a real entry-price advantage when the Australian company is building for global revenue, not only the domestic market.

A 2025 government review recommended strengthening the RDTI rather than weakening it.4 The review recommended both broader eligibility for software-driven R&D and longer-tenured eligibility for companies that scale beyond the A$20M turnover threshold. The political consensus around the RDTI has held across changes of government for over a decade.

The risk is not abolition. The risk is parameter drift. A tightening of the eligible-activities definition, an extension of the audit cycle, or a reduction in the refundable offset rate would each compress the arbitrage. None has been announced.

The superannuation pool and the slow turn

Australia’s superannuation system holds A$4.3 trillion in retirement assets.2 The legal mandate to invest in retirement savers’ best financial interests has historically been read as a preference for liquid, listed, low-cost beta. That reading is changing.

Regulatory pressure from APRA, political pressure from successive governments, and competitive pressure between large industry funds have combined to push allocations into unlisted assets, including private equity and venture capital. Industry fund allocation to unlisted growth assets sits in the high single digits to low double digits across the major funds.2 A 1% incremental allocation to venture and growth equity across the system is large relative to the current Australian VC market.

The political reform is two-sided. The 2025 superannuation tax change applied a 30% concessional rate to balances above A$3M from 1 July 2026, with parameters still under negotiation.3 The same review process recommended easing the regulatory barriers to superannuation investment in high-growth firms.4 The policy direction appears more supportive of private-market and growth-company exposure, but the route into venture remains allocator-specific and slow.

The implication for seed-stage funds is structural. The potential domestic LP base is widening, but access remains concentrated and relationship-driven. The fund-level competition for capital is intensifying. The commercial relationships that determine whether an industry-fund allocator commits to a vintage are forming now.

Where the regulatory architecture lives

Four Necessity-aligned regulated sectors, each with a mature statutory regime.

Financial services: APRA prudential standards for ADIs; ASIC market and conduct supervision; recent additions covering crypto and stablecoin licensing; the new operational resilience standard CPS 230 effective 1 July 2025.5 T2 vendors selling into APRA-regulated entities have a multi-year procurement horizon and a structural switching-cost advantage.

Energy: AEMO Integrated System Plan committing A$122 billion across generation, storage, and transmission investment by 2050; AER regulatory revenue determinations on five-year cycles; ARENA grant programmes targeting renewables R&D.6 The transition pipeline is funded, regulated, and hard to reverse, even if individual projects slip.

Healthcare and biotech: TGA software-as-medical-device framework; PBS reimbursement pathway; clinical trial sponsor requirements harmonised with ICH GCP. TGA-regulated companies can build a credible approval record that supports later entry into selected Asia-Pacific markets.

Critical minerals: A$4 billion Critical Minerals Strategy 2023-2030; Critical Minerals Office at the Department of Industry; FIRB review thresholds reduced for sensitive sector transactions in 2024. Australia’s resource base in lithium, rare earths, and copper sits inside a tightening export-control architecture aligned with allied economies.

What the doctrine looks for

A specific deal profile. An Australian-domiciled company eligible for RDTI claiming. A T1 or T2 product positioned inside one of the four regulated sectors. A go-to-market sequence that wins regulated-buyer revenue first, then expands the deal size as the buyer’s regulatory burden grows. A cap table that anticipates a Series B or C lead from a North American or European investor once revenue starts shifting outside Australia.

The Australian companies that match this profile are not numerous. The pool is constrained by domestic talent supply in regulated-sector engineering and product roles. But the entry valuations are competitive against U.S. comparables, the RDTI offset extends runway, and the local regulatory familiarity can produce faster early T1 licensing or T2 procurement traction than a comparable U.S. company would face in a larger, more fragmented market.

Risks

The domestic addressable market is small. Companies that build only for Australian regulated buyers will not produce venture-scale outcomes. The doctrine accepts this and assumes early-stage entry with explicit international revenue path.

The political economy of the superannuation system can shift. A change of government, a fiscal-pressure event, or a high-profile fund failure could redirect superannuation policy. The doctrine treats LP-base composition as a portfolio construction question rather than a fund-level certainty.

The exit path is thinner than in the United States. ASX micro-cap listings exist but have priced down. Strategic exits to North American or European acquirers remain the dominant path. Companies whose product is too Australia-specific in regulatory configuration may face thin acquirer interest.

Chapter 6 turns to New Zealand, where the entry valuation discount is largest, the failure rate is highest, and the capital efficiency of the regulated-sector Necessities is at its sharpest.

Footnotes

  1. Australian Taxation Office and Department of Industry, Science and Resources, R&D Tax Incentive overview FY25. ↩ ↩2

  2. Australian Prudential Regulation Authority, Quarterly superannuation industry publication, late 2025 release. Allocation ranges aggregated across MySuper products and major retail/industry funds; precise allocation per fund varies materially. ↩ ↩2 ↩3

  3. Australian Treasury, Better Targeted Superannuation Concessions, enacted 2025; effective 1 July 2026 per Australian Taxation Office. ↩ ↩2

  4. Australian Government, strategic examinations of Australia’s R&D system and innovation policy, both delivered to Government in 2025. Specific recommendations on RDTI and superannuation-VC interface. ↩ ↩2

  5. APRA Prudential Standard CPS 230 Operational Risk Management, in force 1 July 2025. ↩

  6. Australian Renewable Energy Agency annual reports, 2024-25 vintage. ↩